American Society of Clinical Oncology (ASCO)

ASCO 2023 Melanoma In-Depth

ASCO 2023: Continued Success With Immunotherapy in Melanoma

By

Mark L. Fuerst

Publish Date June 29, 2023

At ASCO 2023, researchers reported positive results with nivolumab plus relatlimab, a cancer vaccine plus pembrolizumab, and pembrolizumab alone in patients with melanoma.

ASCO 2023 Genitourinary Cancer In-Depth

ASCO 2023: Improving Genitourinary Cancer Care

By

Jody A. Charnow

Publish Date June 29, 2023

At ASCO 2023, investigators reported results from phase 3 trials that could improve therapeutic approaches to bladder, prostate, and kidney cancer.

ASCO 2023 Her2+ Breast Cancer In Depth

ASCO 2023: Treatment De-Escalation and the Role of Age in HER2+ Breast Cancer

By

Alan P. Lyss, MD

Publish Date June 28, 2023

Studies presented at ASCO 2023 answered some questions about de-escalating treatment and how age impacts outcomes in patients with HER2-positive breast cancer.

ASCO 2023 Gastrointestinal Cancer In-Depth

ASCO 2023: Will Gastrointestinal Cancer Studies Affect Practice?

By

Mary Ellen Schneider

Publish Date June 27, 2023

Research presented at ASCO 2023 highlights the latest developments in gastrointestinal cancer treatment.

ASCO 2023 Lymphoma In-Depth

ASCO 2023: Lymphoma Research Could Change Practice   

By

Tori Rodriguez, MA, LPC, AHC

Publish Date June 26, 2023

Studies presented at the ASCO Annual Meeting 2023 highlighted new developments in lymphoma that could lead to changes in practice.

ASCO 2023 CAR-T In-Depth

ASCO 2023: Ground-Breaking Results With CAR T-Cell Therapies  

By

Victoria Forster, PhD

Publish Date June 22, 2023

Studies of CAR T-cell therapies presented at ASCO 2023 broke new ground and may change practice, according to researchers.

ASCO 2023

Sunvozertinib Shows Activity in NSCLC Patients After Platinum Chemo Failure

By

Leah Lawrence

Publish Date June 21, 2023

Sunvozertinib has demonstrated antitumor activity in patients with advanced NSCLC who have EGFR exon 20 insertions.

ASCO 2023 Multiple Myeloma In-Depth

ASCO 2023: Studies Clarify Role of Immunotherapy in Multiple Myeloma

By

Bryant Furlow

Publish Date June 20, 2023

Studies from ASCO 2023 revealed new potential standards of care for multiple myeloma and a first for bispecific antibody therapy.

ASCO 2023

Data Support Adjuvant Pembrolizumab as Standard Care in Stage IIB/C Melanoma

By

Leah Lawrence

Publish Date June 20, 2023

Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, updated data suggest.

ASCO 2023

Adjuvant Gemcitabine-Cisplatin Improves PFS in Nasopharyngeal Carcinoma

By

Leah Lawrence

Publish Date June 19, 2023

Gemcitabine plus cisplatin provides benefits over 5-fluorouracil plus cisplatin as adjuvant treatment for nasopharyngeal carcinoma, phase 3 data suggest.